title: Older age of rheumatoid arthritis onset is associated with higher activation status of peripheral blood CD4(+) T cells and disease activity.
abstract: Rheumatoid arthritis (RA) is a chronic inflammatory disease, with a clinical manifestation both systemic and in joints. It has been suggested that age at disease onset and/or patients' age have influence on disease activity and clinical outcome. The reasons for the different course of RA in older people are not known; however, the activation status of peripheral blood lymphocytes could be responsible. Our aim was to relate expression of activation markers in peripheral blood CD4(+) T cells of RA patients with patients' age and/or onset age and disease activity measured by DAS28. Seventy RA patients were included into the immunological study. Two separation criteria were performed: based on age of RA onset and on the biological age of patients. We examined different activation markers, CD69, CD25, CD95 and human leucocyte antigen D-related (HLA-DR), on the CD4(+) T cell surface. Division of RA patients in 10-year intervals at 40, 50 and 60 years revealed that RA patients with later disease onset were characterized by higher DAS28. This phenomenon was not limited to the division at 60 years of age but, surprisingly, the major differences were found for the 40-year onset division. Analysis of all four components of DAS28 revealed that disease activity in older disease onset was dependent on all components. Older-onset RA patients had a higher percentage of CD4(+) CD25(+) and CD4(+) CD95(+) T cells. Summarizing the major differences in DAS28 and activation status of CD4(+) T cells observed for onset of disease at 40 years seems to be the most informative about the immunological status of RA patients.
authors.affiliation: Departments of Pathophysiology, Medical University of Gdańsk, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Pawłowska
authors.forename: Z
authors.initials: Z
authors.lastname: Smoleńska
authors.forename: A
authors.initials: A
authors.lastname: Daca
authors.forename: J M
authors.initials: JM
authors.lastname: Witkowski
authors.forename: E
authors.initials: E
authors.lastname: Bryl
mesh_terms: D000328:Adult; D017668:Age of Onset; D015703:Antigens, CD / Q000032:analysis / Q000276:immunology; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis / Q000276:immunology; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology*; D015415:Biomarkers / Q000097:blood; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D015331:Cohort Studies; D005260:Female; D006684:HLA-DR Antigens / Q000032:analysis / Q000276:immunology; D006801:Humans; D053645:Interleukin-2 Receptor alpha Subunit / Q000032:analysis / Q000276:immunology; D037181:Lectins, C-Type / Q000032:analysis / Q000276:immunology; D008213:Lymphocyte Activation; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012720:Severity of Illness Index; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D019014:fas Receptor / Q000032:analysis / Q000276:immunology; D000099192:CD69 Antigens
chemical_list: D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D018501:Antirheumatic Agents; D015415:Biomarkers; D006684:HLA-DR Antigens; D053645:Interleukin-2 Receptor alpha Subunit; D037181:Lectins, C-Type; D008727:Methotrexate; D011241:Prednisone; D019014:fas Receptor; D000099192:CD69 Antigens